English Polski
Vol 19 (2024): Continuous Publishing
Review paper
Published online: 2024-05-27

open access

Page views 60
Article views/downloads 33
Get Citation

Connect on Social Media

Connect on Social Media

Beyond Unrecognized: Heart Failure with Supranormal Ejection Fraction – A Review of Current Knowledge on a Novel Heart Failure Phenotype

Paweł Maeser1, Robert Morawiec1, Katarzyna Piestrzeniewicz1, Jarosław Drożdż1
DOI: 10.5603/fc.98823

Abstract

Heart failure with supranormal ejection fraction (HFsnEF) is a newly recognized and distinct phenotype in cardiology, specifically refers to the coexistence of heart failure symptoms with an ejection fraction ≥ 65%. HFsnEF patients, predominantly women, exhibit smaller left ventricular volumes, lower NT-proBNP levels, and lower rates of coronary artery disease (CAD) and atrial fibrillation (AF) compared to other HF with preserved ejection fraction subgroups. Treatment options for HFsnEF are limited, with suboptimal response to standard pharmacotherapy. Prognosis in HFsnEF is associated with increased mortality rates as ejection fraction exceeds 60–65%. Refinement of diagnostic and treatment approaches is crucial for improving outcomes in this challenging patient group.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. McDonagh Th, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  2. Wehner GJ, Jing L, Haggerty CM, et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J. 2020; 41(12): 1249–1257.
  3. Huang Z, Jiang Y, Zhou Y. Heart failure with supra-normal left ventricular ejection fraction: state of the art. Arq Bras Cardiol. 2021; 116(5): 1019–1022.
  4. Bozkurt B, Coats A, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure. 2021; 23(3): 352–380.
  5. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017; 14(10): 591–602.
  6. Kittleson M, Panjrath G, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction. Journal of the American College of Cardiology. 2023; 81(18): 1835–1878.
  7. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400(10354): 757–767.
  8. Greene SJ, Spertus JA, Tang W, et al. Heart failure across the range of mildly reduced and preserved ejection fraction in the united states. Circ Heart Fail. 2023; 16(5): e010430.
  9. Metra M, Teerlink J, Cotter G, et al. Effects of serelaxin in patients with acute heart failure. N Engl J Med. 2019; 381(8): 716–726.
  10. van Essen BJ, Tromp J, Ter Maaten JM, et al. Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction. Eur J Heart Fail. 2023; 25(1): 35–42.
  11. Horiuchi Yu, Asami M, Ide T, et al. Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: Insight from the JROADHF study. Eur J Heart Fail. 2023; 25(7): 989–998.
  12. Rosch S, Kresoja KP, Besler C, et al. Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction. Circulation. 2022; 146(7): 506–518.
  13. Forrest IS, Rocheleau G, Bafna S, et al. Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure. Eur J Heart Fail. 2022; 24(11): 2118–2127.
  14. Imamura T, Hida Y, Ueno H, et al. Clinical implication of supra-normal left ventricular ejection fraction in patients undergoing transcatheter aortic valve replacement. J Clin Med. 2023; 12(23).
  15. Murat S, Cavusoglu Y, Yalvac HE, et al. Assessment of clinical characteristics of cardiac amyloidosis as a potential underlying etiology in patients diagnosed with heart failure with preserved ejection fraction. Kardiol Pol. 2022; 80(6): 672–678.
  16. Oghina S, Bougouin W, Bézard M, et al. The impact of patients with cardiac amyloidosis in hfpef trials. JACC Heart Fail. 2021; 9(3): 169–178.
  17. Martens P, Hanna M, Valent J, et al. Supra-normal left ventricular ejection fraction in cardiac amyloidosis. Clin Res Cardiol. 2023; 112(3): 441–443.
  18. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40(40): 3297–3317.
  19. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  20. Solomon S, McMurray J, Anand I, et al. Angiotensin–Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019; 381(17): 1609–1620.
  21. Solomon SD, Claggett B, Lewis EF, et al. TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016; 37(5): 455–462.
  22. Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018; 20(8): 1230–1239.
  23. Ferreira JP, Packer M, Butler J, et al. Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. Eur J Heart Fail. 2022; 24(7): 1148–1153.
  24. Arnold SV, Silverman DN, Gosch K, et al. Beta-Blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction. JACC Heart Fail. 2023; 11(8 Pt 1): 893–900.
  25. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400(10354): 757–767.
  26. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2022; 386(21): e57.
  27. McMurray J, Solomon S, Inzucchi S, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med . 2019; 381(21): 1995–2008.
  28. Kosiborod MN, Petrie MC, Borlaug BA, et al. STEP-HFpEF DM Trial Committees and Investigators, STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389(12): 1069–1084.
  29. Siddiqi TJ, Anker SD, Filippatos G, et al. Health status across major subgroups of patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2023; 25(9): 1623–1631.
  30. Shah S, Segar MW, Kondamudi N, et al. Supranormal left ventricular ejection fraction, stroke volume, and cardiovascular risk: findings from population-based cohort studies. JACC Heart Fail. 2022; 10(8): 583–594.
  31. Maredziak M, Bengs S, Portmann A, et al. Microvascular dysfunction and sympathetic hyperactivity in women with supra-normal left ventricular ejection fraction (snLVEF). Eur J Nucl Med Mol Imaging. 2020; 47(13): 3094–3106.
  32. Uijl A, Savarese G, Vaartjes I, et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021; 23(6): 973–982.